// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.

Kim Anna Reiss - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ipilimumab

A phaseII study of antiPD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Shukui Qin - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Fluorouracil

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairead Geraldine McNamara - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Irinotecan

A phaseII multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-nave metastatic castration-resistant prostate cancer.

Enrique Grande - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Prediction of neoadjuvant chemotherapeutic efficacy by CTC and cfDNA in patients with locally advanced breast cancer.

Ge Ma - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).

Qiang Zhang - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Trial in progress abstract phase I trial of 5-aza-4-thio-2-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

M. Cecilia Monge B - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Decitabine

SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).

Vincenza Conteduca - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

TP53

COX-2 expression and mesenchymal-transition status on circulating tumor cells to predict survival in patients with nasopharyngeal carcinoma: A prospective analysis.

Yongjiang Li - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).

Steven J. Chmura - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.

Pai-Chi Teng - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Prognostic impact of baseline circulating tumor cells (CTCs) detected by the isolation by size of epithelial tumor cells (ISET) in locally advanced head and neck squamous cell carcinoma (LAHNSCC): Results of a prospective study.

Thiago Bueno Oliveira - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Erbitux

CTC versus biopsy tissue sequencing:A concordance analysis of genomic copy number profile from mCRPC patients (pts).

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Safety and clinical outcomes of GT0918 (Proxalutamide), a potent androgen receptor (AR) blocker, in patients with mCRPC progressing on standard (SoC) and experimental therapies: Phase I/II trial.

Nicholas J. Vogelzang - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).

Mark Jesus Mendoza Magbanua - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bevacizumab

Tumor volume, circulating tumor cells, and cfDNA changes during radiotherapy in patients with head and neck cancer.

Sweet Ping Ng - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Chronobiological features of melatonin receptors (MT1) expression in breast cancer cells.

Alexandre Tavartkiladze - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Melatonin

Clinical value of CTC in predicting the efficacy of treatment in breast cancer.

Yidong Zhou - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Nivolumab and ipilimumab treatment in prostate cancerwith an immunogenic signature (NEPTUNES).

Yien Ning Sophia Wong - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ipilimumab

Copyright © 2026. QuantiNova All rights reserved